Published in Clin Prostate Cancer on June 01, 2005
Administration of zoledronic acid enhances the effects of docetaxel on growth of prostate cancer in the bone environment. BMC Cancer (2006) 1.23
Pain and health-related quality of life in patients with advanced solid tumours and bone metastases: integrated results from three randomized, double-blind studies of denosumab and zoledronic acid. Support Care Cancer (2013) 1.12
RAD001 (Everolimus) inhibits growth of prostate cancer in the bone and the inhibitory effects are increased by combination with docetaxel and zoledronic acid. Prostate (2008) 1.09
Optimizing clinical benefits of bisphosphonates in cancer patients with bone metastases. Oncologist (2010) 0.86
Role of denosumab in the management of skeletal complications in patients with bone metastases from solid tumors. Biologics (2012) 0.85
Systematic literature review and network meta-analysis comparing bone-targeted agents for the prevention of skeletal-related events in cancer patients with bone metastasis. Oncologist (2015) 0.85
Prostate cancer cells modulate osteoblast mineralisation and osteoclast differentiation through Id-1. Br J Cancer (2009) 0.83
RANK/RANK-L/OPG in patients with bone metastases treated with anticancer agents and zoledronic acid: a prospective study. Int J Mol Sci (2013) 0.81
Combined inhibition of the BMP pathway and the RANK-RANKL axis in a mixed lytic/blastic prostate cancer lesion. Bone (2010) 0.80
Managing bone loss and bone metastases in prostate cancer patients: a focus on bisphosphonate therapy. Rev Urol (2008) 0.80
A SNP in CYP2C8 is not associated with the development of bisphosphonate-related osteonecrosis of the jaw in men with castrate-resistant prostate cancer. Ther Clin Risk Manag (2010) 0.76
Bisphosphonate-Induced Osteonecrosis of the Maxilla Resembling a Persistent Endodontic Lesion. Iran Endod J (2015) 0.75
Skeletal morbidity rates over time in patients with bone metastases from solid tumors reported in bone modifying agents randomised trials. J Bone Oncol (2012) 0.75
RANKL: A promising circulating marker for bone metastasis response. Oncol Lett (2016) 0.75
The use of zoledronic acid in Japanese men with stage D2 prostate cancer. Oncol Lett (2010) 0.75
Cryoablation combined with zoledronic acid in comparison with cryoablation and zoledronic acid alone in the treatment of painful bone metastases. Exp Ther Med (2014) 0.75